...
首页> 外文期刊>Toxicology Letters: An International Journal Providing a Forum for Original and Pertinent Contributions in Toxicology Research >Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress
【24h】

Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress

机译:吉非替尼体内和体外大鼠心肌细胞心脏毒性的分子机制:细胞凋亡和氧化应激的作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Gefitinib (GEF) is a multi-targeted tyrosine kinase inhibitor with anti-cancer properties, yet few cases of cardiotoxicity has been reported as a significant side effect associated with GEF treatment. The main purpose of this study was to investigate the potential cardiotoxic effect of GEF and the possible mechanisms involved using in vivo and in vitro rat cardiomyocyte model. Treatment of rat cardiomyocyte H9c2 cell line with GEF (0,1, 5, and 10 mu M) caused cardiomyocyte death and upregulation of hypertrophic gene markers, such as brain natriuretic peptides (BNP) and Beta-myosin heavy chain (beta-MHC) in a concentration-dependent manner at the mRNA and protein levels associated with an increase in the percentage of hypertrophied cardiac cells. Mechanistically, GEF treatment caused proportional and concentration-dependent increases in the mRNA and protein expression levels of apoptotic markers caspase-3 and p53 which was accompanied with marked increases in the percentage of H9c2 cells underwent apoptosisecrosis as compared to control. In addition, oxidative stress marker (heme oxygenase-1, HO-1) and the formation of reactive oxygen species were increased in response to GEF treatment. At the in vivo level, treatment of Wistar albino rats for 21 days with GEF (20 and 30 mg/kg) significantly increased the cardiac enzymes (CK, CKmb, and LDH) levels associated with histopathological changes indicative of cardiotoxicity. Similarly, in vivo GEF treatment increased the mRNA and protein levels of BNP and beta-MHC whereas inhibited the antihypertrophoic gene (alpha-MHC) associated with increased the percentage of hypertrophied cells. Furthermore, the mRNA and protein expression levels of caspase-3, p53, and HO-1 genes and the percentage of apoptotic cells were significantly increased by GEF treatment, which was more pronounced at the 30 mg/kg dose. In conclusion, GEF induces cardiotoxicity and cardiac hypertrophy in vivo and in vitro rat model through cardiac apoptotic cell death and oxidative stress pathways. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
机译:吉非替尼(GEF)是一种具有抗癌特性的多靶点酪氨酸激酶抑制剂,但据报道很少有心脏毒性病例是与GEF治疗相关的重大副作用。这项研究的主要目的是研究GEF的潜在心脏毒性作用以及使用体内和体外大鼠心肌细胞模型可能涉及的机制。用GEF(0、1、5和10μM)处理大鼠心肌细胞H9c2细胞系会导致心肌细胞死亡和肥大基因标志物(例如脑钠肽(BNP)和β-肌球蛋白重链(β-MHC))的上调在与肥大性心肌细胞百分比增加相关的mRNA和蛋白质水平上呈浓度依赖性。从机制上讲,GEF处理导致凋亡标记caspase-3和p53的mRNA和蛋白质表达水平成比例和浓度依赖性地增加,与对照相比,伴随着凋亡/坏死的H9c2细胞百分比显着增加。另外,响应于GEF处理,增加了氧化应激标记物(血红素加氧酶-1,HO-1)和活性氧的形成。在体内水平,用GEF(20和30 mg / kg)治疗Wistar白化病大鼠21天,可显着增加与指示心脏毒性的组织病理学变化相关的心脏酶(CK,CKmb和LDH)水平。同样,体内GEF处理可增加BNP和β-MHC的mRNA和蛋白水平,而抑制抗肥大基因(α-MHC)则可增加肥大细胞的百分比。此外,通过GEF处理,caspase-3,p53和HO-1基因的mRNA和蛋白质表达水平以及凋亡细胞的百分比显着增加,在30 mg / kg剂量下更为明显。总之,GEF通过心脏凋亡细胞死亡和氧化应激途径在体内和体外大鼠模型中诱导心脏毒性和心脏肥大。 (C)2016 Elsevier Ireland Ltd.保留所有权利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号